Home
HelpTest Code AATHR Thrombophilia Profile, Plasma and Whole Blood
Ordering Guidance
Multiple coagulation profile tests are available. See Coagulation Profile Comparison for testing that is performed with each profile.
Shipping Instructions
Send all specimens in the same shipping container.
Specimen Required
Both blood and plasma are required.
Patient Preparation:
1. Patient should not be receiving Coumadin (warfarin), heparin, direct thrombin inhibitors (argatroban, dabigatran), or direct factor Xa inhibitors (apixaban, rivaroxaban, and edoxaban).
2. Specimen must be collected prior to initiation of anticoagulants and thrombolytic therapy.
3. If patient has been recently transfused, it is best to perform this study pretransfusion, if possible.
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD), light-blue top (3.2% sodium citrate)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
3. Label specimen as whole blood.
Specimen Type: Platelet-poor plasma
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vial (polypropylene preferred)
Specimen Volume: 5 mL in 5 plastic vials; each containing 1 mL
Collection Instructions:
1. Specimen must be collected prior to factor replacement therapy.
2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
4. Aliquot plasma (1-2 mL per aliquot) into 5 separate plastic vials leaving 0.25 mL in the bottom of centrifuged vial.
5. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally, -40° C or below.
Additional Information: Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
Useful For
Evaluating patients with thrombosis or hypercoagulability states
Detecting a lupus-like anticoagulant; dysfibrinogenemia; disseminated intravascular coagulation/intravascular coagulation and fibrinolysis
Detecting a deficiency of antithrombin, protein C, or protein S
Detecting activated protein C resistance (and the factor V Leiden [p.Arg534Gln, historically known as R506Q] variant if indicated)
Detecting the prothrombin F2 c.*97G>A variant (historically known as G20210A)
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| AATHI | Thrombophilia Interpretation | No | Yes |
| PTSC | Prothrombin Time (PT), P | Yes, (order PTTP) | Yes |
| APTSC | Activated Partial Thrombopl Time, P | Yes, (order APTTP) | Yes |
| DRV1 | Dilute Russells Viper Venom Time, P | Yes, (order DRVI1) | Yes |
| TTSC | Thrombin Time (Bovine), P | Yes | Yes |
| CLFIB | Fibrinogen, Clauss, P | Yes, (order FIBTP) | Yes |
| DIMER | D-Dimer, P | Yes, (order DDITT) | Yes |
| ATTF | Antithrombin Activity, P | Yes | Yes |
| CFX | Protein C Activity, P | Yes | Yes |
| PSF | Protein S Ag, Free, P | Yes, (order PSTF) | Yes |
| APCRV | Activated Protein Resistance V, P | Yes | Yes |
| PTNT | Prothrombin G20210A Mutation, B | Yes | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| ATTI | Antithrombin Antigen, P | Yes | No |
| FACTV | Coag Factor V Assay, P | Yes | No |
| F_7 | Coag Factor VII Assay, P | Yes | No |
| F_9 | Coag Factor IX Assay, P | Yes | No |
| F_10 | Coag Factor X Assay, P | Yes | No |
| F_11 | Coag Factor XI Assay, P | Yes | No |
| F_12 | Coag Factor XII Assay, P | Yes | No |
| F8A | Coag Factor VIII Activity Assay, P | Yes | No |
| RTSC | Reptilase Time, P | Yes | No |
| F_2 | Coag Factor II Assay, P | Yes | No |
| PCAG | Protein C Ag, P | Yes | No |
| F5DNA | Factor V Leiden (R506Q) Mutation, B | Yes | No |
| PNP | Platelet Neutralization Procedure | No | No |
| PTMSC | PT Mix 1:1 | No | No |
| APMSC | APTT Mix 1:1 | No | No |
| PST | Protein S Ag, Total, P | No | No |
| DRV2 | DRVVT Mix | No | No |
| DRV3 | DRVVT Confirmation | No | No |
| SOLFM | Soluble Fibrin Monomer | No | No |
| PTFIB | PT-Fibrinogen, P | No | No |
| HEXLA | HEX LA, P | No | No |
| SFX | Protein S Activity, P | Yes | No |
Testing Algorithm
Initial testing includes prothrombin time (PT); activated partial thromboplastin time (aPTT); dilute Russell's viper venom time (dRVVT); thrombin time (bovine); fibrinogen; D-dimer; antithrombin activity; protein C activity; protein S antigen, free; prothrombin G20210A variant; activated protein resistance V; and thrombophilia interpretation.
If the PT is greater than 13.9 seconds, then the PT mixing study will be performed at an additional charge.
If the aPTT is 38 seconds or more, then the aPTT mixing study will be performed at an additional charge.
If the aPTT mix result is 38 seconds or more and thrombin time is less than 35.0 seconds (no evidence of heparin), then the platelet neutralization procedure will be performed at an additional charge.
If the dRVVT ratio is 1.20 or more, then the dRVVT mixing study and dRVVT confirmation will be performed at an additional charge.
If the thrombin time is 25.0 or more seconds, then the reptilase time will be performed at an additional charge.
If the fibrinogen result is less than 150 mg/dL or clinically indicated, then PT-fibrinogen will be performed at an additional charge.
If the D-dimer result is greater than 500 ng/mL fibrinogen equivalent units (FEU), then soluble fibrin monomer testing will be performed at an additional charge.
If the free protein S antigen result is less than 65% for men and women 50 years of age or older and less than 50% for women and girls younger than 50 years of age, then the total protein S antigen test will be performed at an additional charge.
If the protein C activity is less than 70% with no evidence for an acquired decrease in protein C activity, then protein C antigen testing may be performed at an additional charge.
If the antithrombin activity is less than 80% with no evidence of an acquired decrease in antithrombin activity, then antithrombin antigen testing will be performed at an additional charge.
If the activated protein C resistance (APC) ratio is less than 2.3 or the baseline APC aPTT is prolonged, then factor V Leiden (R506Q) variant analysis will be performed at an additional charge.
If appropriate, protein S activity, coagulation factor assays, or hexagonal lupus anticoagulant will be performed, at an additional charge, to clarify significant abnormalities in the screen test results.
For more information see Thrombophilia Profile
Special Instructions
Method Name
PTSC, APTSC, DRV1, TTSC, APCRV: Optical Clot-Based
CLFIB: Clauss
DIMER, PSF: Latex Immunoassay (LIA)
ATTF, CFX: Chromogenic
PTNT: Direct Variant Analysis
AATHI: Medical Interpretation
Reporting Name
Thrombophilia ProfSpecimen Type
Plasma Na CitWhole blood
Specimen Minimum Volume
Plasma: 5 mL total, 5 plastic vials each containing 1 mL, Whole blood: 1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma Na Cit | Frozen | 14 days | |
| Whole blood | Ambient (preferred) | 14 days | |
| Frozen | 14 days | ||
| Refrigerated | 14 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Reference Values
An interpretive report will be provided.
Day(s) Performed
Weekly
Report Available
4 to 7 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
See Individual Test IDsCPT Code Information
81240-F2 PTNT
85300-ATTF
85303-CFX
85306-PSF
85307-APCRV
85379-DIMER
85384-CLFIB
85390-26-AATHI
85610-PTSC
85613-DRV1
85670-TTSC
85730-APTSC
81241-F5 (coagulation factor V) (eg, hereditary hypercoagulability) gene analysis, Leiden variant (if appropriate)
85210-Factor II (if appropriate)
85220-Factor V (if appropriate)
85230-Factor VII (if appropriate)
85240-Factor VIII (if appropriate)
85250-Factor IX (if appropriate)
85260-Factor X (if appropriate)
85270-Factor XI (if appropriate)
85280-Factor XII (if appropriate)
85301-Antithrombin antigen (if appropriate)
85302-Protein C antigen (if appropriate)
85305-Protein S antigen, total (if appropriate)
85306-Protein S activity (if appropriate)
85366-Soluble fibrin monomer (if appropriate)
85385-PT-Fibrinogen (if appropriate)
85597-Platelet neutralization for lupus inhibitor (if appropriate)
85598-Hex LA (if appropriate)
85611-PT mix 1:1 (if appropriate)
85613-DRVVT mix (if appropriate)
85613-DRVVT confirmation (if appropriate)
85635-Reptilase (if appropriate)
85732 - APTT Mix 1:1 (if appropriate)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| AATHR | Thrombophilia Prof | 98125-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| CLFIB | Fibrinogen, Clauss, P | 48664-7 |
| 603184 | Thrombophilia Interpretation | 69049-5 |
| 603325 | Reviewed by | 18771-6 |
| RVR1 | DRVVT Screen Ratio | 15359-3 |
| 21803 | Prothrombin G20210A Mutation, B | 24475-6 |
| APTSC | Activated Partial Thrombopl Time, P | 14979-9 |
| PTSEC | Prothrombin Time (PT), P | 5902-2 |
| TTSC | Thrombin Time (Bovine), P | 46717-5 |
| DIMER | D-Dimer, P | 48067-3 |
| ATTF | Antithrombin Activity, P | 27811-9 |
| CFX | Protein C Activity, P | 27818-4 |
| PSF | Protein S Ag, Free, P | 27821-8 |
| APCR | APCRV Ratio | 13590-5 |
| INT55 | Interpretation | 48591-2 |
| INRSC | INR | 6301-6 |
| 21804 | PTNT Interpretation | 69049-5 |
| 21806 | PTNT Reviewed By | 18771-6 |